Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Innate Pharma SA

< Previous 1 2 3 4 Next >
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Outcome of Innate Pharma’s 2023 Annual General Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of shares and voting rights of Innate Pharma as of May 1, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Provides Update on Silicon Valley Bank Exposure
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of February 1, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
From Innate Pharma SA
Via Business Wire
Tickers IPHA SNY
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports Third Quarter Financial Results
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
From Innate Pharma SA
Via Business Wire
Tickers IPHA
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.